| Drug (Aptamer) |
ClinicalTrials.gov Identifier: |
Phase |
Condition |
Sponsor |
| ARC1905 |
NCT00950638 |
Phase I
Active, not recruiting |
Age-Related Macular Degeneration |
Ophthotech Corporation |
| E10030 |
NCT01089517 |
Phase II
Active, not recruiting |
Age-Related Macular Degeneration |
Ophthotech Corporation |
| E10030 |
NCT00569140 |
Phase I
Completed |
Age-Related Macular Degeneration |
Ophthotech Corporation |
| ARC1905 |
NCT00709527 |
Phase I
Completed |
Age-Related Macular Degeneration |
Ophthotech Corporation |
| EYE001 anti-VEGF aptamer |
NCT00021736 |
Phase II
Phase III
completed |
Macular Degeneration
Choroidal Neovascularization |
Eyetech Pharmaceuticals |
| REG1 |
NCT00113997 |
Phase I
completed |
Healthy, improve control of "blood thinning" |
National Heart and Lung, and Blood Institute
(NHLBI) |
| EYE001 |
NCT00056199 |
Phase I
completed |
Hippel-Lindau Disease |
National Eye Institute (NEI) |
| pegaptanib sodium (Macugen) |
NCT00215670 |
Phase II
Phase III, completed |
Age-Related Macular Degeneration |
Eyetech Pharmaceuticals , Pfizer |
| Pegaptanib sodium |
NCT00312351 |
Phase IV, terminated |
Macular Degeneration |
Eyetech Pharmaceuticals , Pfizer |
| Pegaptanib sodium |
NCT00321997 |
Phase II
Phase III, completed |
Age-Related Macular Degeneration |
Eyetech Pharmaceuticals , Pfizer |
| pegaptanib sodium (Macugen) |
NCT00040313 |
Phase II, completed |
Diabetic Macular Edema |
Eyetech Pharmaceuticals , Pfizer |
| AS1411 |
NCT01034410 |
Phase II, terminated |
Acute Myeloid Leukemia |
Antisoma Research |
| NOX-E36 |
NCT00976729 |
Phase I, completed |
Chronic Inflammatory Diseases
Type 2 Diabetes Mellitus
Systemic Lupus Erythematosus |
Noxxon Pharma AG |
| NOX-A12 |
NCT01194934 |
Phase I, completed |
Hematopoietic Stem Cell Transplantation |
Noxxon Pharma AG |
| NOX-A12 |
NCT00976378 |
Phase I, completed |
Autologous Stem Cell Transplantation |
Noxxon Pharma AG |
| ARC1779 |
NCT00694785 |
Phase II, has been withdrawn prior to enrollment |
Von Willebrand Disease |
Archemix Corp. |
| ARC1779 |
NCT00632242 |
Phase II, completed |
Purpura, Thrombotic Thrombocytopenic
Von Willebrand Disease Type-2b |
Archemix Corp. |
| ARC19499 |
NCT01191372 |
Phase I
Phase II , no started |
Hemophilia |
Archemix Corp. |
| Macugen (Pegaptanib Sodium) |
NCT01487044 |
|
Diabetic Macular Edema |
Retina Institute of Hawaii |
Drug: Macugen (Pegaptanib Sodium) |
NCT01487070 |
Phase I, completed |
PDR |
Retina Institute of Hawaii |
